This chapter presents several significant arguments and goes into extensive
detail about the ethical and regulatory issues. It also describes how conducting and
marketing clinical studies is impacted by treating in silico models. Complex biological
systems and the impact of various therapies throughout the course of the disease can be
assessed with the use of in silico models. Because of this, it is crucial to uphold both
legal compliance and the necessary code. Several important ethical principles that must
be upheld are also taken into consideration, such as autonomy, informed consent, and
privacy preservation. How models adhere to the regulatory concerns and remedies
mandated by the FDA and EMA is also covered. The role of modeling in the safe and
dependable design of medications and equipment is further highlighted by various
techniques. Finally, it is emphasized how crucial it is to adhere to the set standards in
order to win patients' faith in the model's actual use.
Keywords: Diabetes, In silico, Ethical issues, Regulatory guidelines, Personalized treatment, Standardization, FDA, EMA.
